Pharmaceutical Technology Is Now PharmTech: A Sharper Name for a Smarter Industry

Navigating FDA Shakeups and Obesity Drug Wars

Behind the Headlines Episode 28

Ask the Expert

Outsourcing Partnerships Fuel Global Biopharma Discovery and Scale-Up

Drug Digest February 2026 

How It Helps Avoid Facility and Equipment Problems

A “Plan, Prevent, Prove” Approach

David Schoneker is president, Black Diamond Regulatory Consulting, LLC

New Excipient Development–Part 1

The term “new excipient” can refer to different product types, according to David Schoneker, president, Black Diamond Regulatory Consulting. Excipient innovations include new chemical entities (NCEs), products designed for higher levels of use, new routes of administration, or specific new patient populations. They also encompass new grades of existing excipients, pre-mixed or co-processed materials, and slight chemical modifications. In some cases, substances are adapted from alternate industries, such as foods and cosmetics, to serve pharmaceutical functions.

Adoption of new excipients by formulators is often a slow process. The development of actual novel NCE excipients is particularly rare, primarily due to the prohibitive amountof safety data required for approval. Furthermore, the pharmaceutical industry typically exhibits a lack of acceptance for these novel materials unless they provide a solution to a problem that no other existing substance can address.

In terms of application, small-molecule drugs currently drive the majority of new excipient development due to the magnitude of potential uptake in the market, according to Schoneker. However, the commercialization of large molecules may occasionally depend on the creation of a truly novel excipient, often resulting in collaborative development between excipient manufacturers and pharmaceutical companies.

Ultimately, the push for these new products is driven the need to fulfill an unmet need within a pharmaceutical company or a desire by an excipient manufacturer to expand their market. By creating new products, these companies aim to compete more effectively with existing excipients currently on the market.

Watch the interview above to learn more about what goes into the development of a new excipient. Dave will be participating in the workshop, “Risk Based Framework for Development of New Excipient Products”, at 

 being held in Nashville from May 4-6, 2026.

Videos

In part 1 of a multi-part series, David Schoneker, president, Black Diamond Regulatory Consulting, explains the difference between a new excipient and a novel excipient and what goes into developing a new excipient.

Peter Belden, Tjoapack, discusses how the rise of specialized medicines for smaller patient populations is necessitating more flexible, redundant packaging capacity to manage complex global distribution requirements.

Scaling for Growth: Inside Tjoapack’s US Expansion Strategy

Peter Belden, Chief Commercial Officer at Tjoapack, explains that the company’s US expansion is primarily driven by the rapid acceleration of specialized medicines and treatments for smaller, often underserved patient populations.

This shift in drug development has created a significant need for flexible, nimble outsource packaging services that can adapt to unique requirements more effectively than larger, traditional contract packagers. By targeting mid-market and emerging biopharma manufacturers, Tjoapack is positioning itself to support the entire lifecycle of these complex molecules.

The current expansion builds upon previous investments in Europe to create a redundant, two-continent platform designed for long-term growth over the next 5 to 10 years. This infrastructure allows Tjoapack to offer a wide range of capabilities, including oral solid doses, injectables, and cold chain management, as well as specialized compliance packaging. The addition of expanded automation and physical capacity ensures that the company can handle both standard scalable solutions and highly customized packaging needs.

Ultimately, these strategic investments transform Tjoapack into a global supply chain hub, providing the planning tools and resources necessary for manufacturers to reach patients in 40 to 50 countries. By offering global logistics support and coordination, Tjoapack aims to be the preferred partner for biopharma sponsors navigating the complexities of commercializing medicines in both major Western markets and emerging global territories.

Senior Director for Quality and Regulatory Affairs in Science, Policy, and Intelligence under Global Regulatory Affairs, Novo Nordisk

Andrew Chang and Steven Falcone, Novo Nordisk share how real-time digital monitoring, smart sensors, and a globally connected manufacturing network are shaping pharma's QMS future.

Inside Novo Nordisk's Digital Quality Management Strategy

Andrew Chang, senior director for Quality and Regulatory Affairs, Novo Nordisk, and Steven Falcone, head of the AIR-Q Group, Novo Nordisk, discuss Novo Nordisk's vision for a digitally connected manufacturing network and the role of real-time monitoring in modern pharmaceutical quality management.

Falcone gives a high-level overview of Novo Nordisk's quality management system, emphasizing the central role of process owners, cross-functional teams responsible for ensuring consistency across the company's global manufacturing network. These process owners oversee critical areas such as drug product sterility and manufacturing science and technology, working to align operations and set a shared direction for continuous improvement.

Falcone describes the real-time digital monitoring infrastructure in place across Novo Nordisk's fill-finish sites. Automated visual inspection systems examine every unit coming off production lines, while dense sensor networks track filling operations as they happen. "During the filling process, there's an incredible amount of sensors that are monitoring the performance of the filling operation in real-time digitally," Falcone explains. The company also utilizes tag rooms equipped with highly visible HMI screens and closed-circuit TV to give teams across different locations live visibility into manufacturing performance.

"We have a very big ambition to establish a globally interconnected digital network to support our manufacturing,” Chang continues. This vision, which includes a standardized manufacturing network, reflects Novo Nordisk's broader belief that real-time digital monitoring represents the future of pharmaceutical quality systems.

Chang adds an industry-wide perspective, noting that PDA's AI advisory and expert working group is actively engaging with regulatory agencies to help shape software validation requirements for manufacturing and quality management systems as guidance in this fast-evolving field continues to develop.

Andrew Chang and Steven Falcone, Novo Nordisk, share how real-time digital monitoring, smart sensors, and a globally connected manufacturing network are shaping pharma's QMS future.

CPHI America’s Agenda | Image Courtesy of Informa Markets

The conference program at CPHI Americas 2026, taking place in Philadelphia from June 2–4, a

ddresses a wide range of challenges that are reshaping how drugs are developed, manufactured, and brought to market

 The event is drawing senior leaders from across the pharmaceutical supply chain, including manufacturers, biotech companies, suppliers, and service providers. This year's agenda has been structured around themes of evolving regulatory frameworks, AI in drug discovery, supply chain resilience, and the future of biologics and advanced therapies.

On the regulatory side, sessions will examine shifts in US policy and approaches to risk-based decision making.

 A session titled "FDA in Flux: Navigating the New Regulatory Landscape" will feature Molly Klote, former director of the HHS Office for Human Research Protections, alongside Highlander Health co-founder Amy Abernethy. Patrick Day, Principal Consultant, Lachman Consultants, will lead a separate session on global risk management and risk-to-value transformation, which will focus on practical framing for development and regulatory affairs teams managing cross-border portfolios.

How Will CPHI Americas Cover Biotech Funding and Supply Chain Stability?

As investment in biologics continues to accelerate, sessions will explore what that means for funding strategies and the innovation pipeline.

 Murray Aitken, executive director, IQVIA Institute, will examine the evolving biotech innovation ecosystem. A panel featuring leaders from Likarda, BioLabs, Epivax, and Morgan Stanley will discuss the financing of breakthroughs in the sector. A dedicated session on cell and gene therapy will look at how this segment of the market is developing within the U.S. context.

Supply chain resilience remains a persistent topic of concern.

 Luiz Barberini will present on Bayer's approach to procurement and external manufacturing. Mayank Nagar, Dr. Reddy's, will lead a session on the future of strategic alliances in pharma.

Digitalization and cybersecurity also feature prominently.

 A session on ransomware, social engineering, and supply chain threats, featuring Derek Booth, supervisory special agent, US Secret Service, speaks directly to the vulnerabilities that pharmaceutical organizations face as they digitize operations and rely more heavily on interconnected systems. Emily Lewis, UCB, will lead a session on embedding AI across drug discovery.

A session on market strategy will address how contract manufacturing organizations can differentiate themselves and communicate their value more effectively, with speakers from Bandwidth Solutions, LGM Pharma, and Veranova.

Sarah Griffin, event manager, CPHI Americas, noted in a press release,

"CPHI Americas brings together leaders throughout the pharmaceutical supply chain to address the challenges shaping drug development and manufacturing." She added "this year's agenda focuses on the areas having the greatest impact on the sector, including regulatory shifts, AI and biologics, providing attendees with practical insight they can apply within their organizations."

The event is part of a global portfolio spanning 11 international events across Europe, the Americas, the Middle East, and Asia.

How Does CPHI Americas Compare with Its Global Counterparts?

The CPHI portfolio extends well beyond Philadelphia, as CPHI & PMEC China, held annually in Shanghai, draws more than 110,000 attendees and more than 3,600 local and international exhibitors, making it Asia's largest pharmaceutical event.

The exhibition spans active pharmaceutical ingredients, natural extracts, machinery, laboratory instruments, packaging, biotech, and traditional Chinese medicine, a breadth that speaks to the country's dual strengths in heritage ingredients and advanced pharmaceutical development.

 The 2026 edition will feature expanded zones including traditional Chinese medicine pavilions and next-generation active pharmaceutical ingredient showcases.

As Orhan Caglayan, executive vice president of the Pharma Portfolio, Informa Markets, noted in a press release,

"The growth of CPHI & PMEC China mirrors the extraordinary pace of innovation in China, solidifying its position as the ultimate destination for sourcing, supply chain optimization, and forging strategic partnerships."

The challenges discussed in Philadelphia are inseparable from the international dynamics that events like CPHI & PMEC China bring into sharp focus. CPHI is also putting on events in Italy and India in 2026.

Informa Markets. CPHI Americas 2026 to focus on regulatory shifts, AI and biotech innovation. Press release. Philadelphia, PA; April 16, 2026. 

https://www.cphi.com/americas/agenda/events/conference-agenda/

Informa Markets. The largest pharma show in Asia makes its return to Shanghai this June 2026. Press release. March 2, 2026. 

https://www.prnewswire.com/news-releases/the-largest-pharma-show-in-asia-makes-its-return-to-shanghai-this-june-2026-302700982.html

Articles

CPHI Americas 2026 in Philadelphia convenes senior pharmaceutical supply chain stakeholders to address regulatory volatility, AI-enabled R&D, biologics investment, and supply chain resilience. Regulatory programming emphasizes US policy shifts, risk-based decision-making, and global risk-to-value approaches for cross-border portfolios. Biotech sessions span ecosystem trends, financing pathways, and cell and gene therapy maturation in the US. Operational tracks prioritize procurement/external manufacturing strategy, alliance models, and escalating cybersecurity threats amid digitalization. The broader CPHI portfolio highlights global interdependence, exemplified by Shanghai’s CPHI & PMEC China scale and expanded sourcing and innovation zones.

CPHI Americas 2026 tackles pharma's pressing challenges such as: regulatory shifts, AI in drug discovery, biologics innovation, and supply chain resilience.

Inside CPHI Americas 2026 Agenda

Interpack 2026 Preview | Image Courtesy of groninger


This year’s Interpack meeting arrives on May 7, 2026, in Düsseldorf, Germany, with some of the biggest manufacturers in the EU presenting their upcoming innovations. This year's exhibition includes a range of technology areas based around development and manufacturing operations. Modular packaging lines for parenteral and solid-dose products, automated carton handling, and precision counting equipment will be on display from the Uhlmann Group.

 Filling and closing systems for liquid pharmaceutical and consumer healthcare products, alongside digital process monitoring tools, will be presented by groninger.

 Labeling materials and application technology for pharmaceutical and hazardous goods applications, including tamper-evident and variable-data solutions, will be covered by HERMA.

What Does Increasing Complexity in Pharmaceutical Packaging Require?

For Uhlmann Group, the answer involves positioning its member companies as a coordinated portfolio rather than a set of independent equipment vendors.

"As a group, we combine technologies, expertise, and experience to provide expert consulting and pioneering, modular solutions, thereby actively driving change in the packaging ecosystem." said Prof. Dr. Matthias Niemeyer, CEO, The Uhlmann Group, in a press release.

Uhlmann Pac-Systeme's exhibit centers on two lines with direct relevance to parenteral and solid-dose packaging.

 The PTC 200 is a modular solution for packaging parenteral products in carton mono-packages; the BEC 500 combines a blister machine and cartoner in a single unit. Both are designed for flexibility across packaging materials. Visitors can explore these lines through a digital presentation, including three-dimensional visualizations and an interactive holowall display that walks through line functions and process steps.

Groninger approaches the complexity question through a different lens: the formulation itself.

 Throat sprays without preservatives, eye drops with modified viscosities, novel topical creams, each one introduces new demands on filling processes. Batch sizes are contracting, changeovers are accelerating, and hygiene requirements are stricter.

"Our customers operate in markets that have become significantly faster and more complex, while quality requirements continue to rise," says Otto Helmle, vice president sales consumer Healthcare and Cosmetics, Groninger, said in a press release.

"With flexcare, we rely on a platform concept that combines stable processes and high precision with the ability to react quickly and flexibly to new demands." The flexcare platform's modular design allows a wide range of viscosities to be processed reliably, with retrofit options intended to protect longer-term capital investment.

For labeling operations, Sven Pleier, Key Account Manager, HERMA, said in a press release,

 "Today, labels have to do far more than simply convey information. What is needed are solutions that save material and costs, can be sourced flexibly and at the same time reliably meet even demanding requirements in terms of durability, safety and variable marking."

How Are Digitalization and Material Sustainability Shaping Equipment Decisions?

On the digital side, groninger's VisionX Pink platform is designed to make machine data transparent and enable early detection of process deviations.

 Real-time data availability and process capability supports analysis, and an integrated dashcam function allows video-based fault diagnosis.

"Digitalization must never be an end in itself," Frieder Kanitz, CEO, Groninger, stated in the press release.

 "It has to support the people at the machine — through transparency, better decision-making and access to relevant knowledge."

On materials, KOCH Pac-Systeme is introducing a new folding carton module for its KMO platform that uses a horizontal cartoning process with side product insertion for fully automated handling.

 Folding cartons are gaining ground in part because of their recyclability and material efficiency, and in part because of evolving European packaging regulations. The KMO's standardized modular interfaces mean the machine can be adapted to new material requirements without full line replacement.

Goldfuss Automation’s fully automated feeder with an integrated collaborative robot retrieves pre-packaged blanks from the pallet, opens shipping cartons, and loads blanks directly into a cartoning machine's magazine.

 The system can manage the complete material flow through to the removal of empty cartons and interlayers, reducing manual handling in packaging areas where contamination control, ergonomics, or labor efficiency are concerns.

In labeling, HERMA's focus is on linerless label materials, including InNo-Liner, which requires neither silicone nor liner and has been validated in logistics applications where it reduced waste by approximately 60% and cut costs relative to conventional systems.

 The pharma-specific exhibit covers film-based labels that can be variably printed using ultraviolet lasers, creating permanent, smudge-proof, and disinfectant-resistant marks without ink or ribbons.

"What is always crucial is the interaction of material, adhesive, printing process and reliable application in the line," noted Marc Trapp, Head of Sales Industrial Labels, HERMA, in the press release.

Uhlmann Group Holding GmbH & Co. KG. Interpack 2026: One Group. One Responsibility: Uhlmann Group showcases integrated solutions for complex packaging requirements. Press release. April 8, 2026.

groninger & co. gmbh. Filling Processes in Transition: How groninger Keeps Sensitive Products Under Control. Press release. April 14, 2026. 

HERMA GmbH. HERMA label solutions at interpack 2026: Labels for growing demands. Press release. Filderstadt, Germany; April 2026.

Interpack 2026 in Düsseldorf will spotlight EU packaging innovation spanning parenteral and solid-dose lines, liquid filling/closing, and advanced labeling. Uhlmann emphasizes an integrated group portfolio with modular parenteral cartoning and combined blister–cartoner systems, supported by digital line visualization. groninger frames complexity through sensitive formulations, smaller batches, faster changeovers, and heightened hygiene, addressed via the modular flexcare platform and VisionX Pink transparency tools. HERMA prioritizes durability, safety, variable marking, and waste reduction through linerless materials and laser-enabled, disinfectant-resistant printing.

Interpack 2026 previews filling, labeling, and packaging equipment from Uhlmann Group, groninger, and HERMA designed for pharmaceutical manufacturers.

Must-see Exhibits at Interpack 2026

Disclaimer: The views and opinions expressed in this article are those of the author and do not necessarily reflect the views or positions of Umoja Biopharma



Christopher Lewis, Umoja Biopharma, sat down with 

 to discuss how AI is reshaping quality management, workforce development, and data utilization in the pharmaceutical industry.

Check out the 2-part video Interview with Lewis:

How AI Is Transforming Biopharma Quality and Compliance

AI Tools That Drive Competency in Complex Pharma Environments

PharmTech: How Do You Think About the Risks of Implementing AI in Biopharma?

Lewis: It really comes down to risk management and balance. You have to weigh the capabilities and capacity that AI brings against the need to keep humans meaningfully involved throughout the process — not just at the end, but at every step. That means integrating human oversight from a conceptual standpoint, through qualification and validation, and all the way into day-to-day use. When you have a human in the loop at each of those stages, you end up with a balanced, risk-based approach that's appropriate for the environment we operate in.

How Do You Measure Whether AI Tools Are Delivering Value in Quality Operations?

There are a few key metrics I'd focus on. First, cycle time. How long does it take to work through an investigation? That's a meaningful indicator of whether these tools are creating real efficiency. Second, hands-on time. Is automation freeing people up, or are they spending just as many hours on these tasks as before? And third, recurrence rates. Are we seeing the same issues and deviations come back around? I'd expect those numbers to go up initially, because AI is likely to surface repeat issues that may have slipped past human reviewers. But over time, as we use that information to get to true root cause, those rates should come down. That downward trend is where you really see the value.

What Other AI Applications in Pharma Have Caught Your Attention?

A few things stand out. The first is learning and performance. Our industry has long been stuck in a model where you generate hundreds of documents and expect people to read them and absorb everything, and that's just not how people learn effectively. AI offers a way to build competency models that are tailored to the individual, the task, or the complexity of the work. In a dynamic environment where people aren't doing the same thing every day, that kind of personalized, point-of-task support is valuable.

The second is predictive analytics, using AI to continuously monitor process performance data and get ahead of problems before they become problems. And the third, is automation of repetitive tasks. We have a lot of highly skilled people in this industry spending significant time on low-complexity, repetitive work. That kind of work can breed complacency, and complacency leads to mistakes. If we can use AI to handle that, we free those people up to apply their expertise where it matters.

What Emerging AI Opportunity Excites You Most?

It’s utilizing data. Pharma has never had a problem generating data. The challenge has always been extracting it and making sense of it in a way that drives real decisions. Whether it's process monitoring, product quality, stability profiles, or risk assessment, the data is already there. What AI gives us is the ability to use it, to pull it together across systems and get meaningful, actionable insights out of it. We've put enormous time and effort into collecting this data. Now we finally have tools that can help us put it to work.

AI adoption in biopharma quality hinges on balanced, risk-based implementation with continuous human-in-the-loop oversight spanning concept, qualification/validation, and routine use. Value should be demonstrated via operational metrics: investigation cycle time, hands-on effort, and deviation recurrence trends—recognizing recurrence may rise initially as repeat issues are surfaced, then fall with true root-cause resolution. High-impact use cases include AI-enabled competency models and point-of-task performance support, predictive analytics for early signal detection, and automation of low-complexity repetitive work. The largest opportunity is converting abundant, siloed data into actionable cross-system insights for quality and risk decisions.

Christopher Lewis, Umoja Biopharma, shares how AI is reshaping pharma through smarter oversight, personalized training, and actionable data insights.

The Three Ways AI Is Transforming Pharma Quality Management

Paul Smaltz, Senior Vice President of BASF Pharma Solutions, details how the company acts as a strategic partner to the pharmaceutical industry by integrating AI-driven formulation tools, sustainability initiatives, and specialized biopharmaceutical solutions to overcome modern manufacturing challenges. 

Beyond the Excipient: Drug Formulation from Discovery Through Commercialization

As the pharmaceutical landscape shifts toward asset-light models and increased outsourcing, BASF is evolving beyond its role as a traditional excipient manufacturer to provide deep technical expertise and R&D support. Through the implementation of generative AI and the ZoomLab® predictive modeling tool, BASF is helping customers accelerate formulation timelines and solve complex bioavailability issues with unprecedented precision. Smaltz also discusses the BASF commitment to "green transformation," pointing to the company’s goal of reaching net-zero emissions by 2050 while delivering high-performance and sustainable solutions for the growing biopharmaceutical market.

Paul Smaltz, Senior Vice President of BASF Pharma Solutions, explains how the company acts as a strategic partner to the pharmaceutical industry by integrating AI-driven formulation tools, sustainability initiatives, and specialized biopharmaceutical solutions to overcome modern manufacturing challenges. 

Joerg Ahlgrimm, CEO of SK pharmteco, outlines the company's strategic expansion into cell and gene therapy while detailing their commitment to global operational excellence and a culture of employee purpose.

SK pharmteco’s Three-Business-Unit Strategy: Small Molecules, Peptides, and Viral Vectors

SK pharmteco is doubling down on its growth by injecting $100 million into its cell and gene therapy division to complement its established strengths in small molecules and peptides. CEO Joerg Ahlgrimm stresses that the company’s competitive edge lies not just in its global manufacturing footprint across the US, Europe, and Asia, but in a decentralized culture that empowers frontline employees to connect their daily work directly to patient outcomes. Looking toward the next decade, the discussion explores how the integration of AI and a shift toward regionalized supply chains will redefine the CDMO landscape, positioning the firm as a multi-modal leader in an increasingly complex market.

Joerg Ahlgrimm, CEO of SK pharmteco, outlines the company's strategic expansion into cell and gene therapy. He also details their commitment to global operational excellence and a culture of employee purpose.

Christopher Lewis, Umoja Biopharma, explores how AI is revolutionizing pharma training, predicting process issues, and unlocking the value of existing data.

, Christopher Lewis, Umoja Biopharma and president of the Mountain States PDA Chapter, reflects on three transformative ways in which AI is beginning to reshape how pharmaceutical companies operate, from workforce training to predictive analytics and smarter use of existing data.

Lewis challenges a deeply ingrained industry habit: the reliance on document-heavy training models. "Our industry in the past has gotten really stuck in how we handle learning and performance, and we've gotten really stuck in this model of you generate hundreds of documents and expect people to read it and understand everything," he says. In its place, he sees AI enabling personalized, task-specific competency development that meets people where they are, accounting for learning styles, complexity, and the realities of dynamic work environments where no two days are the same.

Beyond training, Lewis highlights AI's potential as a predictive tool, one that continuously monitors process performance data to flag issues before they escalate. This connects directly to his third point regarding AI: the opportunity to automate repetitive, low-value tasks that currently consume the time of highly skilled professionals. When talented people are bogged down in routine work, complacency sets in and mistakes follow, he notes, adding that AI can change that equation.

Lewis zeroes in on a long-standing industry paradox around data. "The issue has never been how much can we generate the data. We've always been really good at generating all the data," he says. "The challenge has always been getting the data out and looking at the data in a really meaningful way to draw meaningful conclusions." For Lewis, AI finally offers a path to unlocking the value already sitting inside pharma's vast data ecosystems across QC testing, supply chains, product stability, and risk assessment, and using it to drive quality and compliance forward proactively.

On April 13, 2026, Regeneron Pharmaceuticals and Telix Pharmaceuticals announced a collaboration, sharing profit and costs 50/50, to develop and commercialize 

 The agreement brings these organizations’ two distinct capability sets together: Regeneron's antibody discovery platforms and clinical oncology portfolio and Telix's radiopharmaceutical development infrastructure, manufacturing capabilities, and global supply chain.

This deal reflects a broader industry pattern of established biologics companies entering the radiopharmaceutical space by partnering with organizations that have already solved the hard manufacturing and logistics problems that make radiopharmaceuticals operationally complex.

Under the terms, Telix will receive an upfront payment of $40 million for access to its radiopharmaceutical manufacturing platform covering four initial therapeutic programs.

 Regeneron holds the option to expand to four additional programs, each carrying additional upfront payments. If Telix opts out of co-funding for any individual program, it becomes eligible instead for up to $535 million in development and commercial milestones per program, plus low double-digit royalties on net sales. The agreement has a potential aggregate milestone value of $2.1 billion across all programs.

The initial programs will draw on antibodies generated from Regeneron's VelocImmune platform, which produces fully human antibodies and bispecific antibodies.

 Alongside therapeutics, the collaboration includes development of radio-diagnostic assets to support patient selection and treatment response monitoring, with Telix leading commercialization of those diagnostics and Regeneron receiving a share of profits.

Why Does the Manufacturing Dimension Matter Here?

Radiopharmaceuticals present manufacturing and supply chain challenges that differ substantially from conventional biologics.

 Short isotope half-lives, radiation handling requirements, specialized logistics, and the need for geographically distributed production all create operational complexity that has historically limited the number of companies able to scale in this space. Telix has built infrastructure specifically around these constraints, as it has operations stationed in every major continent relevant to the industry. This infrastructure is a central part of what Regeneron is accessing through this agreement.

"Telix brings deep expertise in radiopharmaceutical development and infrastructure that complements Regeneron's antibody technologies and oncology portfolio," said Israel Lowy, senior vice president, Regeneron, in a press release.

 "Regeneron is excited to enter the targeted radiopharmaceuticals space and explore the utility of these agents either as monotherapy or rationally combined with our immunotherapy platform, particularly in areas of high unmet patient need such as lung cancer, where our PD-1 inhibitor is a global standard of care."

The collaboration is also notable for its explicit intention to combine radiopharmaceuticals with immunotherapy.

 This is an area of active investigation in the field, but one that introduces additional complexity in trial design, manufacturing coordination, and regulatory strategy. Many coordination challenges come with aligning two distinct modality supply chains for clinical use.

John Lin, senior vice president of Oncology and Antibody Technology Research, Regeneron, stated in the press release,

 "At Regeneron, we follow the science to determine the best therapeutic approach for each disease, continuously expanding our toolbox of treatment modalities — from monoclonal and bispecific antibodies to cell therapies and beyond. Targeted radiopharmaceuticals represent a rapidly emerging frontier in oncology and an exciting opportunity to bring new treatment options to patients in need."

What Does This Signal for the Radiopharmaceutical Field?

The structure of this agreement, a large biologics company paying for access to a specialist's manufacturing platform rather than acquiring it whole, may be instructive for how the radiopharmaceutical sector develops.

 Rather than consolidation through acquisition, this model preserves the operational independence of a manufacturing-capable partner while giving a larger company a path into the modality without a years-long internal build.

Christian Behrenbruch, managing director and group chief executive, Telix, said in the press release,

"The collaboration with Regeneron reflects a highly complementary set of capabilities and a unique opportunity to explore what true 'next gen' biologics-based radiopharmaceuticals can potentially do for patients. We are well positioned to work toward the shared goal of advancing next-generation precision radiopharmaceuticals for patients with hard-to-treat cancers."

What Makes Radiopharmaceuticals Worth the Complexity?

The appeal of radiopharmaceuticals to large pharmaceutical companies goes beyond pipeline diversification.

 Unlike conventional cancer drugs, which must enter a cell and remain inside long enough to cause damage, a process cancer cells can defeat by developing efflux mechanisms, radiopharmaceuticals do not strictly require cellular internalization to be effective. Once a radiopharmaceutical binds to a cancer cell, radioactive decay releases energy that damages the DNA of surrounding cells, killing anywhere from 10 to 30 neighboring cells per molecule. That bystander effect is difficult to replicate with other modalities.

The diagnostic dimension adds another layer of strategic value.

 Because imaging compounds and therapeutic compounds can share the same targeting molecule, physicians can use a diagnostic scan to predict whether a therapeutic will reach its target before treatment begins. This built-in patient selection tool is one that most oncology modalities lack entirely.

Radiopharmaceuticals also show early promise in combination with immunotherapy, precisely the area where Regeneron has existing commercial infrastructure. Radiation-induced cancer cell death can release proteins that alert immune cells to the presence of tumor cells elsewhere in the body, potentially converting immunotherapy-resistant tumors into responsive ones.

Regeneron Pharmaceuticals, Inc. and Telix Pharmaceuticals Limited Announce Strategic Radiopharma Collaboration. Press Release. Published April 13, 2026. 

https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-telix-announce-strategic-radiopharma-collaboration

National Cancer Institute. Radiopharmaceuticals Emerging as New Cancer Therapy. Cancer Currents. Published October 25, 2020. 

https://www.cancer.gov/news-events/cancer-currents-blog/2020/radiopharmaceuticals-cancer-radiation-therapy

Regeneron and Telix formed a 50/50 profit-and-cost collaboration to advance radiopharmaceutical therapeutics across multiple solid-tumor targets, pairing VelocImmune-derived antibodies with Telix’s radiopharma manufacturing and global distribution infrastructure. Telix receives a $40 million upfront for four initial programs, with options for four more; opt-out provisions convert participation into sizable milestones and royalties. The deal underscores manufacturing and logistics as gating capabilities in radiopharma and highlights planned radiopharma–immunotherapy combinations alongside companion diagnostics for patient selection and response monitoring.

Regeneron and Telix announce a 50/50 radiopharma collaboration, combining antibody expertise with specialized manufacturing to develop next-generation cancer therapies.

Featured Content

Pharmaceutical Technology Is Now PharmTech: A Sharper Name for a Smarter Industry

Behind the Headlines Episode 28

Ask the Expert

Drug Digest February 2026

A “Plan, Prevent, Prove” Approach